Tags

Type your tag names separated by a space and hit enter

Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment.
Int J Geriatr Psychiatry 2013; 28(1):34-40IJ

Abstract

BACKGROUND

The Montreal Cognitive Assessment (MoCA) is a brief cognitive schedule that has been developed for the screening of patients with Mild Cognitive Impairment (MCI). MCI is recognized as a high-risk state for Alzheimer's disease. The aim of the present study is to examine the reliability and validity of the Brazilian version of the MoCA test (MoCA-BR) in a sample of older individuals with at least 4 years of education.

METHODS

The MoCA-BR was administered to 112 older adults who were classified into three diagnostic groups according to their cognitive state (Alzheimer's disease, n = 28; MCI, n = 43; normal controls, n = 41). This procedure was based on clinical and neuropsychological data. The performance in the MoCA-BR was compared with the Mini-mental state examination (MMSE) and the Cambridge Cognitive Examination. Diagnostic accuracy was examined with the receiver operating characteristic (ROC) curve analyses.

RESULTS

Cronbach's alpha for the MoCA-BR was 0.75. Temporal stability (retesting after 3 months) using intraclass correlation coefficient was 0.75 (p < 0.001). The sensitivity and specificity of the MoCA-BR for MCI were 81% and 77%, respectively, with a cut-off score of 25 points. The area under the ROC curve for predicting MCI was 0.82 ± 0.06.

CONCLUSIONS

The present results indicate that the MoCA-BR maintains its core diagnostic properties rendering it a valid and reliable tool for the screening of MCI among older individuals with at least 4 years of education.

Authors+Show Affiliations

Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Validation Study

Language

eng

PubMed ID

22368034

Citation

Memória, Cláudia M., et al. "Brief Screening for Mild Cognitive Impairment: Validation of the Brazilian Version of the Montreal Cognitive Assessment." International Journal of Geriatric Psychiatry, vol. 28, no. 1, 2013, pp. 34-40.
Memória CM, Yassuda MS, Nakano EY, et al. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Int J Geriatr Psychiatry. 2013;28(1):34-40.
Memória, C. M., Yassuda, M. S., Nakano, E. Y., & Forlenza, O. V. (2013). Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. International Journal of Geriatric Psychiatry, 28(1), pp. 34-40. doi:10.1002/gps.3787.
Memória CM, et al. Brief Screening for Mild Cognitive Impairment: Validation of the Brazilian Version of the Montreal Cognitive Assessment. Int J Geriatr Psychiatry. 2013;28(1):34-40. PubMed PMID: 22368034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. AU - Memória,Cláudia M, AU - Yassuda,Mônica S, AU - Nakano,Eduardo Y, AU - Forlenza,Orestes V, Y1 - 2012/02/27/ PY - 2011/11/17/received PY - 2012/01/13/accepted PY - 2012/2/28/entrez PY - 2012/3/1/pubmed PY - 2013/5/15/medline SP - 34 EP - 40 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 28 IS - 1 N2 - BACKGROUND: The Montreal Cognitive Assessment (MoCA) is a brief cognitive schedule that has been developed for the screening of patients with Mild Cognitive Impairment (MCI). MCI is recognized as a high-risk state for Alzheimer's disease. The aim of the present study is to examine the reliability and validity of the Brazilian version of the MoCA test (MoCA-BR) in a sample of older individuals with at least 4 years of education. METHODS: The MoCA-BR was administered to 112 older adults who were classified into three diagnostic groups according to their cognitive state (Alzheimer's disease, n = 28; MCI, n = 43; normal controls, n = 41). This procedure was based on clinical and neuropsychological data. The performance in the MoCA-BR was compared with the Mini-mental state examination (MMSE) and the Cambridge Cognitive Examination. Diagnostic accuracy was examined with the receiver operating characteristic (ROC) curve analyses. RESULTS: Cronbach's alpha for the MoCA-BR was 0.75. Temporal stability (retesting after 3 months) using intraclass correlation coefficient was 0.75 (p < 0.001). The sensitivity and specificity of the MoCA-BR for MCI were 81% and 77%, respectively, with a cut-off score of 25 points. The area under the ROC curve for predicting MCI was 0.82 ± 0.06. CONCLUSIONS: The present results indicate that the MoCA-BR maintains its core diagnostic properties rendering it a valid and reliable tool for the screening of MCI among older individuals with at least 4 years of education. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/22368034/Brief_screening_for_mild_cognitive_impairment:_validation_of_the_Brazilian_version_of_the_Montreal_cognitive_assessment_ L2 - https://doi.org/10.1002/gps.3787 DB - PRIME DP - Unbound Medicine ER -